Clinical Trials Logo

Immune System Disorder clinical trials

View clinical trials related to Immune System Disorder.

Filter by:

NCT ID: NCT03385850 Completed - Sepsis Clinical Trials

The Th17/Treg Cells and IL-23/IL-17 Axis and Early Enteral Nutrition in Sepsis

Start date: October 1, 2017
Phase: N/A
Study type: Interventional

The investigators aim to evaluate the roles of Th17/Treg cells and IL-23/IL-17 axis in the mechanisms of early enteral nutrition (EEN) correcting immune imbalance of sepsis by means of improving the intestinal flora disturbance. The results of this study would lay the foundation for revealing the mechanisms of EEN improving immune imbalance of sepsis and provide a new idea to the early treatment of sepsis

NCT ID: NCT03357939 Completed - Clinical trials for Immune System Disorder

Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects

Start date: January 12, 2017
Phase: Phase 1
Study type: Interventional

This healthy male volunteers study will evaluate 148 subjects who will receive a single sub-cutaneous dose of HLX03 (a monoclonal antibody against TNF-a, 40 mg/ 0.8 mL) or Adalimumab(Humira,China spourced,40 mg/0.8 mL injection with a single-use prefilled syringe). This study will involve sampling,pharmacokinetics, safety, tolerability and immunogenicity evaluation of drug levels following administration of HLX03 and the licensed adalimumab products.

NCT ID: NCT03207854 Recruiting - Malignant Neoplasm Clinical Trials

Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

Start date: April 12, 2017
Phase:
Study type: Observational

This research trial collects and stores blood, tissue, and bone marrow specimens from patients with cancer or blood disorders, and healthy volunteers to study the immune system in a variety of different types of experiments, as well as associated clinical data as appropriate, focused on understanding mechanisms of immunotherapy.

NCT ID: NCT00008450 Completed - Clinical trials for Severe Combined Immunodeficiency

Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant

Start date: August 11, 1997
Phase: Phase 1
Study type: Interventional

This pilot clinical trial studies total-body irradiation followed by cyclosporine and mycophenolate mofetil in treating patients with severe combined immunodeficiency (SCID) undergoing donor bone marrow transplant. Giving total-body irradiation (TBI) before a donor bone marrow transplant using stem cells that closely match the patient's stem cells, helps stop the growth of abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may mix with the patient's immune cells and help destroy any remaining abnormal cells. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from happening.